{"id":7572,"date":"2025-12-08T08:00:34","date_gmt":"2025-12-08T07:00:34","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7572"},"modified":"2025-12-08T13:57:22","modified_gmt":"2025-12-08T12:57:22","slug":"prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7572\/prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis\/","title":{"rendered":"Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)"},"content":{"rendered":"","protected":false},"template":"","post-tag":[559,760,704,594,656,850,563,542],"class_list":["post-7572","congress-resource","type-congress-resource","status-publish","hentry","post-tag-alpine","post-tag-american-society-of-hematology","post-tag-ash","post-tag-chronic-lymphocytic-leukemia","post-tag-cll","post-tag-relapsed-refractory-cll-sll","post-tag-sequoia","post-tag-zanubrutinib","congress_resource_type-poster","content_type-reading","disease_state-chronic-lymphocytic-leukemia","molecule-zanubrutinib"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":245,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":false,"key_data_presentation_prioritization":110,"tags":[704,760,656,594,850,563,559],"visible_tags":[704,656,542],"content-type":246,"summary":"","text_app":"&nbsp;\r\n\r\nThis analysis looked at which health factors may help predict outcomes for patients with chronic lymphocytic leukemia treated with zanubrutinib, using data from two large studies. Traditionally, patients with TP53 mutations are considered high-risk, have a worse prognosis, and have a shorter time to disease progression - but in this post-hoc analysis, TP53 mutations were not associated with inferior progression-free survival (PFS) in untreated and relapsed\/refractory CLL. High levels of lactate dehydrogenase (LDH) were associated with worse outcomes, and only in untreated patients with CLL. New risk-stratification tools may need further investigation to assess risk for patients treated with zanubrutinib in CLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"&nbsp;\r\n\r\nThis analysis looked at which health factors may help predict outcomes for patients with chronic lymphocytic leukemia treated with zanubrutinib, using data from two large studies. Traditionally, patients with TP53 mutations are considered high-risk, have a worse prognosis, and have a shorter time to disease progression - but in this post-hoc analysis, TP53 mutations were not associated with inferior progression-free survival (PFS) in untreated and relapsed\/refractory CLL. High levels of lactate dehydrogenase (LDH) were associated with worse outcomes, and only in untreated patients with CLL. New risk-stratification tools may need further investigation to assess risk for patients treated with zanubrutinib in CLL.\r\n\r\n<em>The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"See abstract","congress_resource_cta_link":"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/300997","authors":[7550],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE) \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"Check out the ASH 2025 poster evaluating prognostic model factors in CLL patients treated with zanubrutinib from SEQUOIA and ALPINE by Inhye E. Ahn et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/10\/ASH2025_prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis.jpeg\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/meetings-api.hematology.org\/api\/abstract\/vmpreview\/300997\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-08\",  \r\n  \"keywords\": [\"sequoia and alpine study\", \"zanubrutinib sequoia alpine phase 3 cll study\", \"sequoia clinical trial zanubrutinib\", \"post hoc phase 3 sequoia and alpine study \", \"clinical predictors therapy response\"], \r\n  \"genre\": \"Poster\",   \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Inhye E. Ahn, MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE)\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Evaluation of factors from established prognostic models in patients with chronic lymphocytic leukemia (CLL) treated with zanubrutinib: A post-hoc analysis of two phase 3 studies (SEQUOIA and ALPINE) \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"Check out the ASH 2025 poster evaluating prognostic model factors in CLL patients treated with zanubrutinib from SEQUOIA and ALPINE by Inhye E. Ahn et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/prognostic-models-in-patients-treated-with-zanubrutinib-in-rr-cll-post-hoc-analysis\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7550"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/542"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/559"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/563"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/850"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/594"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/656"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/245"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7572"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}